Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for UroGen Pharma (URGN) over the last 9 years, with Q3 2025 value amounting to 121.28%.

  • UroGen Pharma's EBITDA Margin fell 284100.0% to 121.28% in Q3 2025 from the same period last year, while for Sep 2025 it was 170.81%, marking a year-over-year decrease of 421100.0%. This contributed to the annual value of 140.3% for FY2024, which is 168300.0% down from last year.
  • As of Q3 2025, UroGen Pharma's EBITDA Margin stood at 121.28%, which was down 284100.0% from 206.27% recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's EBITDA Margin ranged from a high of 92.87% in Q3 2024 and a low of 348.2% during Q1 2021
  • Its 5-year average for EBITDA Margin is 173.89%, with a median of 161.09% in 2022.
  • Its EBITDA Margin has fluctuated over the past 5 years, first skyrocketed by 81044900bps in 2021, then crashed by -534100bps in 2025.
  • UroGen Pharma's EBITDA Margin (Quarter) stood at 176.09% in 2021, then increased by 10bps to 159.3% in 2022, then skyrocketed by 31bps to 109.94% in 2023, then crashed by -40bps to 153.44% in 2024, then grew by 21bps to 121.28% in 2025.
  • Its EBITDA Margin was 121.28% in Q3 2025, compared to 206.27% in Q2 2025 and 216.67% in Q1 2025.